Largest Sleep Apnea Trial Backs CPAP For Improving QoL, Not For Lowering Secondary Cardio Events
Executive Summary
In the largest sleep apnea study ever conducted, continuous positive airway pressure (CPAP) did not appear to lower the risk of cardiovascular adverse events including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina in patients with obstructive sleep apnea and known cardiovascular disease. However, patients in the trial only used CPAP a few hours a night, on average, indicating that an easier-to-use version of CPAP might yield better outcomes.
You may also be interested in...
Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial
The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.
Obstructive Sleep Apnea: CPAP Under Pressure As New Market Segments Awaken
An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.